[Effect of the treatment with human recombinant erythropoietin on anemia in children with end-stage kidney failure. French multicenter study].

Background: The production of recombinant erythropoietin, has made large quantities of pure protein available for clinical studies. Published reports have concentrated on patients with end-stage renal disease, who develop transfusion-dependent anemia.

Material And Methods: A total of 58 children aged less than 18 years (mean age: 11.